Collegium Pharmaceutical Inc. (COLL)$34.07
Currency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Collegium Pharmaceutical Inc. (COLL).
DCF ready
Valuation
3.4x
EV/FCF, 29.2% FCF yield
Quality
20.9%
ROIC, 42.0% FCF margin
Growth
20.3%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 1.6x current ratio
Superinvestors
1
Top: Third Avenue Management (0.8%)
Strengths to research
- Revenue compounded at 20.3% over five years.
- Free cash flow compounded at 30.0% over five years.
- Return on equity is strong at 20.9%.
- Free cash flow margin is healthy at 42.0%.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for COLL.
Grade C
58
/ 100
Financial Charts
No financial data available for COLL (annual).
1 superinvestors own COLL
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Third Avenue Management Third Avenue Management | 155,143 | $5M | 0.83% | 0.0% |